Peptide Medicine
Tesamorelin and Egrifta: Approved Indication and Research Context
Evidence checked by HealthRX.com Editorial Team · Last evidence check
What is tesamorelin?
Tesamorelin is a synthetic analog of growth-hormone-releasing hormone. It acts at the pituitary and increases growth hormone and IGF-1. The clinical meaning of that response depends on the product, condition, and outcomes studied. A hormone increase alone is not evidence of improved healthspan or recovery. [1]
What did the pivotal research study?
The pivotal research examined adults with HIV-associated abdominal fat accumulation. Investigators measured visceral adipose tissue and other metabolic outcomes. The diagnosis and fat compartment are essential context: this was not a general trial of cosmetic belly-fat reduction in otherwise healthy adults. [2]
Visceral fat lies within the abdomen around organs. Subcutaneous fat lies beneath the skin. A change in one compartment is not the same as a proportional change in body weight or an improvement in every metabolic outcome.
Why do Egrifta formulations need to be distinguished?
The Egrifta WR label describes differences from Egrifta SV in strength, dose, preparation, and storage. It states that the formulations are not substitutable. A single dose quoted simply as the tesamorelin dose is therefore incomplete. [1]
The product name and its current prescribing information identify the relevant formulation. An unrelated vial labeled tesamorelin cannot be assumed equivalent to a licensed Egrifta product.
What risks does the approved label describe?
The label addresses elevated IGF-1, glucose intolerance or diabetes, fluid retention, hypersensitivity, and other risks. Active malignancy, pregnancy, and specified hypothalamic-pituitary conditions are among its contraindications. Long-term cardiovascular safety has not been established. [1]
These findings are part of the benefit-risk assessment for the approved product. They do not establish that a multi-peptide stack can be made safe by copying a laboratory-monitoring schedule.
Does Egrifta approval apply to compounded tesamorelin?
Approval belongs to the licensed product, not every preparation containing the same ingredient. Egrifta appears in FDA's Purple Book of licensed biological products. FDA explains that biological products do not qualify for the ordinary drug-compounding exemptions under sections 503A and 503B. [3][4]
This distinction is why a statement that tesamorelin is FDA approved needs the product and indication alongside it. It does not establish a general compounded-product pathway or approval for longevity, athletic recovery, or weight management.
Frequently asked questions
Is tesamorelin FDA approved?
Egrifta products containing tesamorelin are approved for excess abdominal fat in adults with HIV-associated lipodystrophy. That approval does not cover every preparation or advertised use.
Is Egrifta a weight-loss medicine?
The Egrifta WR label says it is not indicated for weight-loss management. Its indication concerns a specific fat-distribution condition in adults with HIV.
Are Egrifta WR and Egrifta SV interchangeable?
No. The WR label states that the formulations are not substitutable and describes differences in strength, dose, preparation, and storage.
Do Egrifta trials validate peptide stacks?
No. Evidence about a defined Egrifta product does not establish the benefits or risks of combining tesamorelin with CJC-1295 or other peptides.
Citations
- FDA. Egrifta WR prescribing information, revised March 2025.
- Falutz et al. Metabolic effects of a growth hormone-releasing factor in patients with HIV. 2007.
- FDA Purple Book. Egrifta product record.
- FDA. Compounding and FDA: Questions and Answers.
This guide is educational and is not a substitute for individualized medical advice.
